Barclays Maintains an 'Overweight' on Allscripts-Misys Healthcare (MDRX); Tone Into 4Q: Focus on Eclipsys Growth, Progress on Merger Integration
Tweet Send to a FriendGet Alerts MDRX Hot Sheet
Price: $13.60 +1.64%
Rating Summary:
11 Buy, 16 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
11 Buy, 16 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade MDRX Now!
Barclays maintains an 'Overweight' on Allscripts-Misys Healthcare (NASDAQ: MDRX), PT raised from $23 to $25.
Barclays analyst says, "With the release, we are expecting 4Q EPS of $0.18, in line with consensus expectations of $0.18. For the quarter, we estimate revenues of $335 million, in the range of guidance suggested by Allscripts in November. Given the recurring nature of the bulk of Allscripts' revenue base (around 70% recurring), we'd view Allscripts as having a relatively strong ability to hit its target revenue range, as reflected by the small window given by the company on guided revenue and adjusted EBIT." (Barclays raises FY12 EPS estimate from $0.86 to $0.88)
"Into the release, we are raising our 2011 EPS estimates and price target on MDRX to $25, a reflection in our view of improved visibility on the implementation of Allscripts' meaningful use certified products, and our belief of an on-track integration which could provide further upside through 2012 and beyond."
For more ratings news on Allscripts-Misys Healthcare click here and for the rating history of Allscripts-Misys Healthcare click here.
Shares of Allscripts-Misys Healthcare closed at $22.05 yesterday, with a 52 week range of $15.65-$22.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Barclays analyst says, "With the release, we are expecting 4Q EPS of $0.18, in line with consensus expectations of $0.18. For the quarter, we estimate revenues of $335 million, in the range of guidance suggested by Allscripts in November. Given the recurring nature of the bulk of Allscripts' revenue base (around 70% recurring), we'd view Allscripts as having a relatively strong ability to hit its target revenue range, as reflected by the small window given by the company on guided revenue and adjusted EBIT." (Barclays raises FY12 EPS estimate from $0.86 to $0.88)
"Into the release, we are raising our 2011 EPS estimates and price target on MDRX to $25, a reflection in our view of improved visibility on the implementation of Allscripts' meaningful use certified products, and our belief of an on-track integration which could provide further upside through 2012 and beyond."
For more ratings news on Allscripts-Misys Healthcare click here and for the rating history of Allscripts-Misys Healthcare click here.
Shares of Allscripts-Misys Healthcare closed at $22.05 yesterday, with a 52 week range of $15.65-$22.55.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: Raymond James Downgrades Gevo, Inc. (GEVO) to Market Perform
- Lazard Raises PT on Chicago Bridge & Iron (CBI) to $75
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays, Eclipsys/Allscripts Merger
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
